HGF’s life sciences attorneys understand the challenges associated with commercially focused IP management and can advise on the pertinent issues, from invention conception through to patent term extension, to maximise the value of intellectual property.
As one of Europe’s largest groups of specialist life science attorneys, HGF has the wealth of technical and legal expertise to deliver truly global, commercially-focused strategies.
From protecting new research from Europe’s most prestigious universities, to high-profile oppositions for international healthcare companies on market-leading technologies, the team possesses in-depth legal experience. Particular technical expertise within the group covers the fields of food technology, microbiome for therapeutic purposes, cell and gene therapy, bioinformatics, cleantech, AgBio, immunobiology, gene editing technologies, personalised medicine, bioprocessing and anti-infectives.
In addition, our life sciences attorneys work closely with our IP lawyers in relation to life cycle agreements such as MTAs, R&D collaborations, companion diagnostics, IP licensing, clinical trials through to commercial manufacturing and supply, and litigation.
HGF has been ranked in the Financial Times special report ‘Europe’s Leading Patent Law Firms’ published on the 17th June 2021. More than 10,000 patent attorneys working in patent law …Read article
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
HGF launched the next phase of its European expansion with the opening of its new business in France based in its 22nd European office, in Rennes, France. The office will …Read article
It would have been difficult to miss the recent news that Marks & Spencer has filed trade mark infringement proceedings against German discounter Aldi’s Cuthbert the Caterpillar cake. The filing …Read article
The EPO Boards of Appeal took the decision that from the start of 2021, all Boards of Appeal oral proceedings could be held by videoconference, even if the parties to …Read article
From 1 April 2021, inventors will no longer be notified by the EPO about being named in a patent application. In addition, applicants will no longer be required to indicate …Read article
The long expected decision of the Enlarged Board of Appeal (G 01/19) has been announced by the EPO. The decision relates to the question whether computer simulations can be patented …Read article